['epidermolysis bullosa']
['sd-101 dermal cream (3%)', 'sd-101 dermal cream (6%)', 'vehicle (sd-101 0%)']

        Inclusion Criteria:

          -  Informed Consent form signed by the participant or the participant's legal
             representative; if the participant is under the age of majority but capable of
             providing assent, signed assent from the participant.

          -  Participant (or caretaker) was willing to comply with all protocol requirements.

          -  Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.

          -  Participants 6 months of age and older.

          -  Participants had 1 target wound within a prespecified size range at study entry.

          -  Target wound was at least 21 days or older.

        Exclusion Criteria:

          -  Participants who did not meet all the entry criteria outlined in inclusion criteria.

          -  Selected target wound had clinical evidence of local infection.

          -  Use of any investigational drug within 30 days before enrollment.

          -  Use of immunotherapy or cytotoxic chemotherapy within 60 days before enrollment.

          -  Use of systemic or topical steroidal therapy within 30 days before enrollment (inhaled
             steroids and ophthalmic drops containing steroids were allowed).

          -  Use of systemic antibiotics within 7 days before enrollment.

          -  Current or former malignancy.

          -  Arterial or venous disorder resulting in ulcerated wounds.

          -  Diabetes mellitus.

          -  Pregnancy or breastfeeding during the study (a urine pregnancy test was performed at
             screening for female participants of childbearing potential).

          -  Females of childbearing potential who were not abstinent and not practicing a
             medically acceptable method of contraception.

          -  Known history of cardiac, hepatic, or renal disease.
      